Can I read HTA204 HTA Assessment of Adaptive Trials for Oncology Drugs in Europe on EtoBox?

HTA204 HTA Assessment of Adaptive Trials for Oncology Drugs in Europe by G Bento; O Dumoulin; M Reinert; G Gulotta is a Economics, Econometrics and Finance article available to read on EtoBox.

What is HTA204 HTA Assessment of Adaptive Trials for Oncology Drugs in Europe about?

Objectives: The Canadian Agency for Drugs and Technologies in Health (CADTH) rigorously evaluates drugs in areas with high unmet need such as rare diseases (RD) or oncology, significantly reassessing the manufacturer-submitted incremental costeffectiveness ratio (ICER). We aim to understand how CADTH's pharmacoeconomic reassessments impact the outcomes of price negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) in Canada. Methods: All publicly-available CADTH recommendations for rare and oncology drugs from Q3-2017 to Q2-2022 were identified and reviewed for the submitted and re-analyzed ICERs and any price reduction statements, followed by cross-referencing these drugs to the pCPA Negotiation Status database for their negotiation outcome. Qualitative were conducted to understand the main drivers of the recommendations and outcomes. Results: A total of 37 RD and 140 oncology submissions were identified. Of these, 95% of RD and 79% of oncology drugs received a positive recommendation. On average, CADTH reanalyzed manufacturer-submitted ICERs to be 219% higher. Approximately 83 (47%) submissions had specific price reduction statements of which 30% were .90% discount re

Who reads HTA204 HTA Assessment of Adaptive Trials for Oncology Drugs in Europe?

Author

G Bento; O Dumoulin; M Reinert; G Gulotta

Publisher

Elsevier BV

Published

2022

Language

EN

Field

Economics, Econometrics and Finance (Social Sciences)